Amylyx Pharmaceuticals (AMLX) Accounts Payables (2021 - 2026)

Amylyx Pharmaceuticals has reported Accounts Payables for 6 years, with the latest figure at $5.5 million in Q2 2026.

• On a quarterly basis, Accounts Payables rose 67.97% year-over-year to $5.5 million in Q2 2026; TTM through Jun 2026 was $5.5 million, a 67.97% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, up 19.73% from the prior year.
• Accounts Payables was $5.5 million for Q2 2026 at Amylyx Pharmaceuticals, up from $3.5 million in the prior quarter.
• The five-year high for Accounts Payables was $24.7 million in Q2 2023, with the low at $1.5 million in Q3 2024.
• Average Accounts Payables over 5 years is $8.5 million, with a median of $5.9 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables sank 86.68% in 2024, then surged 259.05% in 2025.
• Over 5 years, Accounts Payables stood at $6.3 million in 2022, then jumped by 252.58% to $22.1 million in 2023, then tumbled by 86.68% to $2.9 million in 2024, then advanced by 19.73% to $3.5 million in 2025, then soared by 57.23% to $5.5 million in 2026.
• The last three Accounts Payables figures came in at $5.5 million (Q2 2026), $3.5 million (Q1 2026), and $3.5 million (Q4 2025), per Business Quant data.